ABAX --- lots of upside Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABAX --- lots of upside

ABAX 83.00

0.0%

Aug 1 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Bogdanoff who wrote (393)	2/2/1998 7:25:00 PM
From: Yo Yo	Read Replies (1) of 492

I spoke with CFO of Hemagen today. Hemagen is the company who just bought the benchtop analyzer business from Dade Behring a couple of weeks ago. CFO's name was Dr. William Franzblau. Dade Behring sold of the analyzer business because it was non-strategic. The good doctor was familiar with ABAX. He said in fact that the ABAX machine is based on the the Dade Behring machine which has been around FOR TWELVE YEARS. Dr. Franzblau said that Hemagen will be competing head-to-head with ABAX. However, Dade Behring's emphasis over the last 12 years has been in human applications, only about 20% in vet market. Dade Behring has been milking the business and has not invested much recently. Hemagen plans to turn that around. It appears that the Dade Behring installed base is about double what the current ABAX installed base, about 3000 machines. Again, most of these are in human applications. Who is the better play? Dr. Franzblau commented that technologically the two machines stack up well (ABAX's machine is slicker). However, the Dade-Behring disks are cheaper. It's a tough one to call at this point. Yo Yo

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next